Introduction
Epithelial ovarian cancer (EOC) is the fourth leading cause of cancer-related deaths in women in the United States and the leading cause of gynecological cancer deaths. Although 80-90% of patients initially respond to first-line chemotherapy agents, carboplatin and paclitaxel, o10-15% remain in complete remission and most patients eventually recur (Alison et al., 2008) with chemoresistant tumors (Jemal et al., 2006; Espey et al., 2007) . Treatment advances have led to an improved 5-year survival of about 45%, but not in overall survival. Thus, recurrence and chemoresistance are major hurdles in the management of patients with ovarian cancer (Schwartz, 2002; Woolas et al., 1993; Clarke-Pearson, 2009) .
Recently it has been postulated that cancer stem cells (CSCs) are not only the potential origin of the tumor, but also the source of recurrence and chemoresistance (Clarke and Fuller, 2006; . Similar to normal stem cells, CSCs are characterized by a high degree of plasticity and capacity for repair and differentiation (Ahmed et al., 2007) . In the ovary, normal stem cells are thought to contribute to healing the ovarian surface after ovulation (Salamanca et al., 2004) . This capacity of normal stem cells to repair may be shared by the CSCs. As such, chemoresistant CSCs that persist after surgery and chemotherapy may 'heal' the cancer and lead to recurrence (Alvero et al., 2009a, b) .
Recently, we reported the identification of two populations of EOC cells, type I and type II (Chen et al., 2007 (Chen et al., , 2008 . Type I/CD44 þ EOC cells have many characteristics associated with CSCs. They are: (1) tumorigenic and can recapitulate the heterogeneity of the original tumor; (2) can form self-renewing spheroids; (3) have high levels of stem cell markers b-catenin, Oct-4 and SSEA-4; (4) have constitutively active IKKb/ necrosis factor (NF)-kB; (5) constitutively secrete IL-6, IL-8, MCP-1 and GRO-a; and (6) are chemoresistant (Alvero et al., 2009a) . Type II/CD44À EOC cells represent a differentiated population and are sensitive to chemotherapy (Chen et al., 2008) . Furthermore, a pure population of type I/CD44 þ EOC cells differentiate in vitro into type II/CD44À EOC cells. This differentiation is accompanied by the loss of stem cell markers and reversion of chemoresistance. The demonstration of this differentiation event is the first step in understanding the molecular regulation of CSC differentiation and may allow the identification of specific signals that regulate this process. It should be emphasized that this differentiation process may yield a more chemosensitive cancer cell population, which may lack the capacity for self-renewal and repair. Moreover, this process may involve molecular events that can change the regulation of apoptosis, cell division, angiogenesis and inflammation. Epigenetic factors have been suggested as the regulatory source promoting the transition from cancer stem-like cells into mature or differentiated cancer cells; including the expression and function of microRNAs (miRNA). miRNAs are B23 nucleotide noncoding RNAs, which negatively regulate gene expression in a sequence specific manner. Numerous studies suggest that miRNAs are key regulators of several fundamental biological processes, including neoplasia and tumor formation (Liu et al., 2005; Valencia-Sanchez et al., 2006; Taylor and Gercel-Taylor, 2008; Yang et al., 2008) . Recently, we observed a distinct miRNA profile between type I/CD44 þ and type II/CD44À EOC cells. In addition, we identified hsa-miR-199a, which is highly expressed in type II/CD44À EOC cells, as a major regulator of the IKKb/NF-kB pathway (Chen et al., 2008) .
Twist1 is a highly conserved transcription factor that belongs to the family of basic helix-loop-helix (bHLH) proteins (Bialek et al., 2004; Cheng et al., 2008c) . Twist1 has been implicated in the differentiation of multiple cell lineages, including muscle, cartilage and osteogenic cells (Lee et al., 1999 (Lee et al., , 2000 Bialek et al., 2004; Ota et al., 2004) . In mice, Twist1 was shown to be required for proper development of the head mesenchyme, somites and limb buds (Lee et al., 2009) . Mice lacking Twist1 die at E10.5 confirming its important role in development and differentiation (Baylies and Bate, 1996) . Recently, Lee et al. (2009) reported the regulation of miR-199/214 in the mouse, suggesting a role for Twist1 and these miRNAs in the development of mice neural cell population. In addition, Twist1 has been shown to be important in the regulation of inflammation and programmed cell death (Cheng et al., 2008b, c) . However, the mechanisms regulating Twist1 expression and function and the manner how Twist1 regulates inflammation, differentiation and programmed cell death has not been described.
In this study, we show that in EOC, Twist1 is associated with the transition of stem-like type I/ CD44 þ cells to type II/CD44À cells, through the regulation of two major pathways: IKKb/NF-kB and PTEN/AKT pathways. Furthermore, we demonstrate that the regulation of these two pathways by Twist1 is through the expression and function of the miRNA cluster MIR199A2/214. Specifically, we show that Twist1, through its regulation of MIR199A2/214, can control the processes of inflammation, differentiation and programmed cell death. -miR-199a in EOC cells corresponds to MIR199A2 gene on chromosome 1 Type I/CD44 þ cells possess a functional and responsive TLR-MyD88-NF-kB pathway, whereas type II/CD44À EOC cells do not. We reported previously that this specific characteristic of the type I/CD44 þ cells is regulated by hsa-miR-199a, which controls the expression of IKKb (Chen et al., 2008) . To determine how hsamiR-199a is regulated, we determined its location in the human genome. Using the NIH gene database, we identified two genes that potentially encode pri-miR199a, the primary precursor of hsa-miR-199a. The first gene is MIR199A1 on chromosome 19 (NCBI GeneID 406976) and the second is MIR199A2 on chromosome 1 (NCBI GeneID 406977). These two sites were predicted from two distinct pre-miR-199a sequences (pre-miR199a-1 and -2) (Sanger Institute miRBase Stem-loop Sequence ID MI0000242 and MI0000281, respectively). To determine which of these sequences correspond to hsa-miR-199a expressed in EOC cells, we evaluated the transcription of pri-miR-199a-1 (from MIRN199A1) and pri-miR-199a-2 (from MIRN199A2) in EOC cells by reverse transcriptase (RT)-PCR. Our results showed that only pri-miR-199a-2 was expressed in EOC cells, with higher expression levels in type II/CD44À than in type I/CD44 þ EOC cells (Figure 1 ). This suggests that the expression of hsa-miR-199a in EOC cells might be due to the differential regulation at the transcriptional level of the MIR199A2 gene.
Results

hsa
Characterization of full-length pri-miR-199a-2 transcript reveals a novel gene cluster Having determined that MIR199A2 was the gene responsible for hsa-miR-199a expression in EOC cells, we then sought to further characterize this gene and its regulation. We first used 5 0 and 3 0 rapid amplification of cDNA ends (RACE) to determine the 5 0 -and 3 0 -ends of this transcript, thus defining the full length of pri-miR199a-2. Using cDNA reverse transcribed from pri-miR199a-2, RACE results showed that the full transcript is 6253 bp in length ( Supplementary Figures 1a and b) . Interestingly, at the 3 0 -end of the pri-miR-199a-2 transcript, we found the precursor sequence for another miRNA pair-hsa-miR-214 and hsa-miR-214*. Thus, we renamed the gene encoding this transcript as MIR199A2/214. This gene encodes a minimum of four miRNA molecules: hsa-miR-199a-5p (or miR-199a), hsa-miR-199a-3p (or miR-199a*), hsa-miR-214 and hsa-miR-214*(GenBank FJ623959). We then evaluated whether the expression of hsa-miR-214 in EOC cells follows the same pattern as that observed with (Figures 2a and b) . By BLASTing the obtained sequence in the NCBI database, a murine pri-miR-199a-2/214 transcript was identified as Dnm3os (NCBI GeneID 474332). The identification of Dnm3os as the mouse homolog of primiR-199a-2/214 (and Dnm3os as mouse MiR199a2/214) was further supported by the sequence and predicted genome context information in the Sanger database (Sanger Institute miRBase Stem-loop Sequence ID MI0000713 and MI0000698). Comparison of the 5 0 -and 3 0 -ends of human MIR199A2/214 with the mouse homolog showed 88 and 89% homology, respectively, with the pre-miR-199a-2 region scoring 99% homology, and the pre-miR-214 region 100% homology (Supplementary Figures 1a and b) . The high sequence conservation of the MIR199A2/214 gene at the premiR-199a-2 and the pre-miR-214 regions in human and mouse indicates important roles of hsa-miR-199a and hsa-miR-214 across species.
Twist1 regulates the hsa-miR-199a/hsa-miR-214 cluster in EOC cells After we confirmed the differential expression of MIR199A2/214 in EOC cells, our next goal was to understand its regulation. Twist1 is a bHLH transcription factor known to regulate the expression of Dmn3os in mouse (Lee et al., 2009) . Therefore, we evaluated the expression of Twist1, the human homolog of murine Twist1, and determined its role in regulating MIR199A2/214 expression in EOC cells. Western blot analysis and quantitative RT-PCR showed that, similar to MIR199A2/214, Twist1 is highly expressed in type II/ CD44À cells but not in type I/CD44 þ EOC cells (Figures 3a and b) .To determine whether Twist1 has a regulatory role over this miRNA cluster in human EOC cells, we used Twist1-specific small interfering RNA (siRNA) to knock down Twist1 expression. Transfection of type II/CD44À cells with Twist1 siRNA is able to significantly decrease Twist1 expression (Figure 4a ). More importantly, analysis of hsa-miR-199a and hsamiR-214 expression levels after Twist1 knockdown showed a parallel decrease on both miRNAs ( Figure 4a ). These results suggest that Twist1 positively regulates the expression of hsa-miR-199a/hsa-miR-214 cluster in EOC cells.
Twist1 inhibits IKKb expression by regulating hsa-miR-199a
Recently we demonstrated that hsa-miR-199a regulates IKKb expression by inhibiting its translation (Chen et al., 2008) . The demonstration that Twist1 regulates hsa-miR-199a expression suggests that Twist1 can regulate IKKb. Therefore, we knocked down Twist1 in type II/CD44À cells (which have high endogenous Twist1 and low IKKb) and monitored the effect on IKKb expression at both the message RNA and protein levels. Twist1 and ovarian cancer G Yin et al through the regulation of hsa-miR-199a, we then sought to reverse the effect of Twist1 knockdown on IKKb by adding exogenous pre-miR-199a. As shown in Figure 5 , the addition of exogenous pre-miR-199a is able to reverse the effect of Twist1 knockdown on the levels of IKKb ( Figure 5 ). This suggests that Twist1 affects IKKb expression through its regulation of hsa-miR199a. The ability of Twist1 to reduce IKKb expression suggests that Twist1 has an inhibitory role in the NF-kB signaling pathway, and may serve as a regulator of inflammation as well as cancer development and progression.
Twist1 negatively regulates NF-kB-dependent cytokine production through IKKb Activation of NF-kB pathway can increase Twist1 expression, and Twist1 has an antagonistic role in NFkB-dependent cytokine expression (Sosic et al., 2003) . However, the specific mechanism by which Twist1 negatively regulates NF-kB is not known. As Twist1, through hsa-miR-199a, can downregulate IKKb, we hypothesize that Twist1 is able to negatively regulate NF-kB-dependent cytokine expression by controlling the levels of IKKb.
In contrast to type I/CD44 þ cells, type II/CD44À EOC cells do not constitutively express cytokines, have high levels of Twist1 and have low levels of IKKb. To show that Twist1 can negatively regulate NF-kBdependent cytokine expression, we knocked down Twist1 in type II/CD44À cells and determined the levels of Rantes, which is known to be regulated by NF-kB. Type II/CD44À EOC cells do not express Rantes ( Figure 6 ). However, knockdown of Twist1 in these cells did not result in an increase in Rantes, although IKKb levels were elevated. This suggests that an additional stimulus may be required to induce Rantes production. Thus, we treated the cells with tumor necrosis factor-a (TNF-a) after Twist1 knockdown. We observed a significant increase in Rantes expression after TNF-a treatment in cells in which Twist1 was Exogenous pre-miR-199a is able to reverse the effect of Twist1 knockdown on the levels of IKKb. Type II/CD44À EOC cells were transfected with siRNA for Twist1. Afterwards, cells were incubated in the presence or absence of pre-miR-199a for additional 72 h and IKKb expression was determined by western blot analysis. Note that the presence of miR199a is able to reverse the effect of Twist1 inhibition.
Twist1 and ovarian cancer G Yin et al knocked down compared with cells transfected with nonspecific siRNA (Figure 6 ). These results suggest that inhibition of Twist1 can activate the NF-kB-dependent Rantes production induced by TNF-a treatment in type II/CD44À EOC cells.
Differential expression of hsa-miR-214 in type I/CD44 þ and type II/CD44À EOC cells corrrelates with and affects the AKT survival pathway As shown above, knockdown of Twist1 affects both hsamiR-199a and hsa-miR-214 levels. To determine whether hsa-miR-199a and hsa-miR-214 have parallel expression in EOC cells, we evaluated the expression of hsa-miR-214 in primary cultures of type I/CD44 þ and II/CD44À EOC cells by RT-PCR. As shown in Figure 2a , hsa-miR-214 follows a similar expression pattern as hsa-miR-199a: it is highly expressed in type II/CD44À EOC cells and mostly undetectable in type I/ CD44 þ cells (Figure 2b ). Taken together with the data described above, these results further support that hsamiR-199a and hsa-miR-214 are regulated as a cluster. As Twist1 is able to regulate the MIR199A2/214 cluster and affect the levels of the miR-199a target, IKKb, our next objective is to determine the effect of Twist1 on the biological function of hsa-miR-214. hsamiR-214 has been shown to directly inhibit PTEN expression at the post-transcriptional level (Cheng et al., 2008b) . PTEN is a critical inhibitor in the AKT survival pathway, an important pathway involved in cancer development as well as chemoresistance (Cheng et al., 2008a) . Therefore, we next examined whether there is a correlation between the levels of hsa-miR-214, PTEN and AKT phosphorylation in EOC cells. As expected, we observed an inverse correlation between hsa-miR-214 and PTEN expression in the two types of EOC cells. Type I/CD44 þ cells are characterized by low levels of hsa-miR-214 and high levels of PTEN expression. In contrast, type II/CD44À cells expressed high levels of hsa-miR-214 and low levels of PTEN (Figure 7a) . Furthermore, this differential phenotype correlates with AKT activity (Figure 7a ) as determined by its phosphorylation status. Type II/CD44À EOC cells have a higher level of phospho-AKT compared with type I/ CD44 þ EOC cells (Figure 7a ). Levels of total AKT was however similar in the two cell types (Figure 7a) . These results suggest a regulatory role for the Twist1/miR-214/ PTEN axis in the control of AKT activity.
To further determine the specificity of each miRNA, we evaluated the levels of IKKb and PTEN expression in type I/CD44 þ cells transfected with hsa-miR-199. As shown in Supplemetary Figure 2 , expression of hsamiR-199 inhibits IKKb expression but does not have any effect on levels of PTEN (Supplementary Figure 2) . 
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In vitro differentiation of type I/CD44 þ EOC cells into type II/CD44À cells is associated with increase in Twist1 expression
Twist1 has been shown to be involved in the process of differentiation (Lee et al., 1999) . Furthermore, we see differential expression of Twist1 in the two subpopulations of EOC cells. We previously demonstrated that pure cultures of type I/CD44 þ EOC cells can differentiate in vitro into type II/CD44À cells (Alvero et al., 2009a) . Therefore, we determined whether Twist1 is associated with this differentiation process. Thus, type I/CD44 þ EOC cells were induced to differentiate as previously described by frequent passing and plating in low confluence (Alvero et al., 2009a) . When the cells showed morphological characteristics of type II/CD44À EOC cells, such as low nuclear/cytoplasm ratio and fast cell-division rate, cells were collected and protein expression was determined by western blot. As shown in Figure 7b , type I/CD44 þ cells do not express Twist1.
However, following differentiation, we observed a significant increase in Twist1 expression. The acquisition of Twist1 is accompanied by a decrease in IKKb, MyD88 and PTEN, and an increase in the phosphorylation of AKT (Threonine 308 and Serine 473).
Recently we reported that type I/CD44 þ EOC cells have stem-like properties and that it has the capacity to differentiate into endothelial cells. This property is not observed in type II/CD44À cells (Alvero et al., 2009b) . Therefore, we determine whether inhibition of Twist1 expression could restore some 'stemness' potential in the type II/CD44À cells. As shown in Supplementary Figure  3a , type I/CD44 þ cells can form tube-like structures when cultured in Matrigel. In contrast, type II/CD44À cells form cell clusters in Matrigel (BD Biosciences, San Diego, CA, USA) (Supplementary Figure 3b) . Inhibition of Twist1 expression in type II/CD44À cells partially restore the capacity of these cells to form tubes (Supplementary Figure 3c) ; this was not observed in type II/CD44À cells transfected with a nonspecific siRNA (Supplementary Figure 3d) .
Discussion
In this study, we demonstrate that Twist1 may regulate the differentiation of type I/CD44 þ ovarian CSCs through the expression and function of a newly identified miRNA cluster, the hsa-miR-199a/hsa-miR-214 (MIR199A2/214.). The differentiation of CSCs into mature cancer cells involves significant changes in their cellular characteristics, particularly in growth rate and capacity for repair and inflammation (Alison et al., 2008) . Twist1 has been implicated in the differentiation of multiple cell lineages, including cancer cells. In this study, we provide evidence that Twist1, through the expression of hsa-miR-199a/hsa-miR-214, can negatively regulate the pro-inflammatory NF-kB pathway and can positively regulate the AKT survival pathway. In addition, we showed the association between Twist1 expression and the activation status of these two pathways during the process of EOC differentiation.
Growing evidence suggest that miRNAs have prominent roles in numerous cellular processes, including growth, proliferation and apoptosis. These suggest that miRNAs are involved in development, genome organization and also human disease, including neurodegenerative, metabolic, inflammatory diseases and a variety of cancers (Bartel, 2004; Alvarez-Garcia and Miska, 2005; Miska, 2005; Valencia-Sanchez et al., 2006; Taylor and Gercel-Taylor, 2008 ). In addition, new evidence suggests that miRNAs may also be involved in the process of differentiation, including stem cell differentiation . Therefore, it is plausible that miRNAs may also have a role in the differentiation process in CSCs.
Ovarian CSCs are characterized by slow cell division, low levels of pAKT and constitutive NF-kB activity. On differentiation into fast-dividing mature ovarian cancer cells, pAKT levels increase and the cells lose the constitutive NF-kB activity. Strikingly, we found that these two processes are regulated by Twist1. Furthermore, we found that the mechanism by which Twist1 promotes these changes is through the expression of a miRNA cluster located in the Dnm3 gene.
Recently, we showed that miR-199a can decrease IKKb expression and therefore negatively regulate NF-kB activity (Chen et al., 2008) . In this study, we identified the full length of pri-miR-199a2 gene, and found hsa-miR-214 located in its 3 0 terminal with hsamiR-199a in the 5 0 -terminal. Interestingly, we found the location of pri-miR-199a2 has overlap with human Dnm3os (opposite strand of intron of Dnm3).
Dnm3os was identified by Loebel et al. (2002) while evaluating Twist-regulated genes in Twist À/À -mutant mice embryos. The gene was named Dnm3os as it is encoded by the opposite strand of Dnm3. Both Dnm3os and Dnm3 are downregulated in Twist À/À mutants (Loebel et al., 2002) . Interestingly, we found that the reported Dnm3os gene sequence corresponds to the hsamiR-199a/hsa-miR-214 cluster and its expression is regulated by Twist1. This was confirmed in the knockdown experiments showing that inhibition of Twist1 by siRNA follows a significant decrease on the expression of both miR-199a and miR-214. Furthermore, we found an active E-box (a promoter element known to be bound by Twist1) in the region of the miR-199/214 cluster (-640 to 0 bp of DNM3os). This is similar as reported in the mouse by Lee et al. (2009) . These data suggest that the role of Twist1 as a transcriptional regulatory factor can be mediated through the expression of miRNAs.
In the mouse, Lee et al. (2009) demonstrated that Twist1 drives the expression of mi199a/214 and is associated with embryonic development; suggesting that Twist1, through micro-RNAs, may regulate processes of differentiation. Our study demonstrate that similar regulation is present in humans, but more specific in human ovarian cancer cells.
Twist1 is temporally expressed during normal development, but it has been reported to be constitutively expressed in some forms of cancer Twist1 and ovarian cancer G Yin et al Kwok et al., 2005; Mironchik et al., 2005) . Similarly, miR-199/214 might be important for development, as described by Lee et al. (2009) and may also have a role in cancer progression. Indeed, we found that the expression levels of hsa-miR-199a, hsa-miR-214 and Twist1 are higher in mature ovarian cancer cells compared with the ovarian CSCs. Similarly, another group reported that miR-214 is differentially expressed in ovarian cancer cells and that its expression correlates with high levels of pAKT (Yang et al., 2008) . An important observation is the differential expression of Twist1, in the ovarian CSCs and the mature ovarian cancer cells. This differential expression correlates with the levels of IKKb and PTEN, respectively. More importantly, this correlation was maintained during the differentiation process from type I/CD44 þ EOC stem cells to type II/CD44À mature cancer cells. The increase in Twist1 levels during the in vitro differentiation process is accompanied by an increase in miR-199a and miR-214, decrease in IKKband PTEN, and increase in AKT activity. It should be emphasized that the in vitro differentiation process is associated with the loss of stem cell phenotype and acquisition of characteristics of a mature cancer cell such as a more rapid cell proliferation. Therefore, we propose that Twist1 activation is an essential factor in the process of transition from ovarian CSCs (type I/ CD44 þ ) into mature fast-dividing ovarian cancer cells (type II/CD44À) (Figures 8a and b) .
In summary, we report the characterization of Twist1 as a regulator of a unique miRNA cluster responsible for the regulation of the IKKb/NFkB and PTEN/AKT pathways and its association of ovarian CSC differentiation. Our data suggest that Twist1 may be an important regulator of 'stemness' in EOC cells. The regulation of MIR199A2/214 expression may be used as a potential therapeutic approach in EOC patients.
Materials and methods
Cell cultures and culture conditions Cells used in these studies were isolated from either ovarian ascites or ovarian cancer tissues and grown as previously described (Kamsteeg et al., 2003) . All patients signed consent forms, and the use of patient samples was approved under the Yale University's Human Investigations Committee (HIC no. 10425).
Reagents
Control siRNA (no. AM4611), control pre-miRNA (no. AM17110), siRNA of Twist1 (no. s14523), pre-miR-199a-5p (no. PM10893) and siPORT NeoFX Transfection Agent (AM4510) were purchased from Ambion (Austin, TX, USA). Rabbit anti-human b-actin antibody was purchased from Sigma (St Louis, MO, USA). Rabbit anti-human MyD88 antibody was purchased from eBioscience (San Diego, CA, USA). Mouse anti-human Twist1 (sc-81417) 
Protein preparation
Protein extraction was carried out as previously described (Kamsteeg et al., 2003) . Briefly, cell pellets were lysed on ice in 1 Â phosphate-buffered saline with 1% NP40, 0.1% SDS and freshly added 20 ml/ml protease inhibitor cocktail (Sigma Chemical) and 2 mM phenylmethylsulfonyl fluoride (Sigma Chemical). Protein concentration was determined by BCA Protein Assay (Pierce Biotechnology, Rockford, IL, USA) and proteins were stored at À80 1C until further use.
SDS-polyacrylamide gel electrophoresis and western blots
A quantity of 20 mg of each protein sample was denatured in sample buffer and subjected to 12% SDS-polyacrylamide gel electrophoresis as previously described (Kamsteeg et al., 2003) . The following antibody dilutions were used: rabbit anti-human MyD88 (1:1000), rabbit anti-human IKKb (1:2000), mouse anti-human Twist1 (1:500), rabbit anti-human phosphoAkt (Ser473, 1:1000), rabbit anti-human phospho-Akt (Thr308, 1:1000), rabbit anti-human PTEN (1:1000) and rabbit anti-human b-actin (1:10 000). Specific protein bands were visualized using enhanced chemiluminescence (Pierce Biotechnology).
Cytokine profiling Levels of Rantes were measured from cell-free supernatants using the Bioplex Pro Cytokine Assay (Biorad, Hercules, CA, USA). Data were acquired using the Bioplex system (Biorad) and analysis was carried out using the Bioplex software as previously described (Koga et al., 2009 ).
Twist1 knockdown and pre-miR-199a transfection
In all, 5 Â 10 5 cells were seeded in 6-cm dish plates and transfected with either 10 nM of control siRNA/miRNA (Ambion) or with the siRNA of Twist1/pre-miR-199a-5p, then incubated in 5% CO 2 incubator for different time point. Transfections were carried out using the siPORT transfection kit (Ambion) in accordance with the manufacturer's protocol.
RNA isolation and RT-PCR
Total RNA was isolated using the RNeasy Mini kit (Qiagen, Valencia, CA, USA) according to the manufacturer's instructions. Reverse transcription was carried out on 2 mg of total RNA using the First Strand cDNA Synthesis kit (Amersham Biosciences, Buckinghamshire, UK) according to the manufacturer's instructions. The primers for pri-miR-199a2 are: forward, 5 0 -ttctccttggaaacagccc-3 0 ; reverse, 5 0 -tgaggaccgggaga mRNA and miRNA quantitative RT-PCR Total RNA was prepared from type I and type II cell lines using the TRIZOL reagent (Invitrogen). Total RNA isolated from each samples was then used as a template for cDNA synthesis, prepared with a first-strand cDNA synthesis kit (Amersham Biosciences) for mRNA and prepared with a Ncode miRNA first-strand cDNA synthesis kit (Invitrogen) for miRNA. The expression of various transcripts was assessed by real-time PCR amplification (50 1C for 2 min; 95 1C for 10 min; (95 1C for 15 s, 60 1C for 1 min; 40 cycles); and 95 1C for 15 s) with Real-Time SYBR Green/Rox PCR supermix (Invitrogen), using the ABI 7500 Real-Time Standard Cycler (Applied Biosystems, Foster City, CA, USA). The primer sets used in this study are: GAPDH (forward 5 0 -ctctgctcct cctgttcgac-3 0 , reverse 5 0 -acgaccaaatccgttgactc-3 0 ); Twist-1 (forward 5 0 -ggcatcactatggactttctctatt-3 0 , reverse 5 0 -ggccagtttgatccc agtatt-3 0 ); IKKb (forward 5 0 -agccagccaagaagagtgaa-3 0 , reverse 5 0 -tctagcagggtgcagaggtt-3 0 ); NRU6B-F (5 0 -acgcaaattcgtgaa gcgttcca-3 0 ); hsa-miR-199a-F (5 0 -cccagtgttcagactacctgttc-3 0 ); and hsa-miR-214-F (5 0 -acagcaggcacagacaggcagt-3 0 ). All PCR reactions were carried out in triplicate and validated by the presence of a single peak in the melt curve analysis. Changes in gene expression were calculated relative to GAPDH using the 2 ÀDCt method, and changes in miRNA expression were calculated relative to NRU6B using the standard curve method.
Statistical analysis
Data were presented as mean ± s.d. (O'Dwyer et al., 1994) . Statistical significance (Po0.05) was determined using oneway analysis of variance with the Bonferonni correction.
